Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity
- 15 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (4) , 929-940
Abstract
CD8+ T cell responses are the foundation of the recent clinical success of immunotherapy in oncologic indications. Although checkpoint inhibitors have enhanced the activity of existing CD8+ T cell responses, therapeutic approaches to generate Ag-specific CD8+ T cell responses have had limited success. Here, we demonstrate that cytosolic delivery of Ag through microfluidic squeezing enables MHC class I presentation to CD8+ T cells by diverse cell types. In murine dendritic cells (DCs), squeezed DCs were ∼1000-fold more potent at eliciting CD8+ T cell responses than DCs cross-presenting the same amount of protein Ag. The approach also enabled engineering of less conventional APCs, such as T cells, for effective priming of CD8+ T cells in vitro and in vivo. Mixtures of immune cells, such as murine splenocytes, also elicited CD8+ T cell responses in vivo when squeezed with Ag. We demonstrate that squeezing enables effective MHC class I presentation by human DCs, T cells, B cells, and PBMCs and that, in clinical scale formats, the system can squeeze up to 2 billion cells per minute. Using the human papillomavirus 16 (HPV16) murine model, TC-1, we demonstrate that squeezed B cells, T cells, and unfractionated splenocytes elicit antitumor immunity and correlate with an influx of HPV-specific CD8+ T cells such that >80% of CD8s in the tumor were HPV specific. Together, these findings demonstrate the potential of cytosolic Ag delivery to drive robust CD8+ T cell responses and illustrate the potential for an autologous cell-based vaccine with minimal turnaround time for patients. Key Points Cytosolic delivery of Ag enables MHC-I presentation by diverse immune cells. Squeeze-engineered APCs prime CD8+ T cells with antitumor activity.Keywords
Funding Information
- Foundation for the National Institutes of Health (R44GM112259)
This publication has 40 references indexed in Scilit:
- Cross-presentation by dendritic cellsNature Reviews Immunology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Lymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitizationBlood, 2012
- Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patientCancer Immunology, Immunotherapy, 2011
- Therapeutic cancer vaccines: are we there yet?Immunological Reviews, 2010
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial NeoplasiaNew England Journal of Medicine, 2009
- Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100Cancer Research, 2009
- Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun deliveryVaccine, 2009
- The known unknowns of antigen processing and presentationNature Reviews Immunology, 2008
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993